The pitch competition showcases six Ontario-based entrepreneurial researchers working in the oncology space to pitch their innovative research ideas to a panel of judges.
The 6th annual Falcons’ Fortunes competition will be held in Toronto on Thursday, April 4, 2019.
FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic
FACIT congratulates portfolio company Fusion Pharma on significant clinical development milestone.
Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors.
"For innovation, open science means open for business", February 6, 2019
"U.S. biotech giant Celgene invests in Ontario-developed blood-cancer drug in potential $1-billion deal", January 29, 2019
FACIT and Triphase Accelerator Announce New Partnership with Celgene for First-in-class WDR5 Leukemia Therapy
Largest transaction to date for Canadian-discovered preclinical asset arises from Ontario collaborators
Triphase Accelerator, together with its majority shareholder FACIT, today announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.
Capital leverages Ontario’s strengths in genomics and informatics, deepens FACIT’s tech portfolio
FACIT's Compass Rose Oncology Fund is providing the follow-on investment. DNAstack also previously received capital from FACIT's early-stage Prospects Oncology Fund, illustrating FACIT's strategy to ensure promising companies grow roots and scale up in Ontario.
FACIT Features: Portfolio company KA Imaging launches first-in-human pilot study to test lung screening x-ray
FACIT congratulates portfolio company KA Imaging on significant clinical development milestone.
KA Imaging, a recent Prospects Fund recipient, is partnering with Grand River Hospital to conduct a pilot study on the use of a high-resolution multi-energy digital x-ray imager for patients with lung nodules.
Strategic appointments of seasoned entrepreneurs add expertise and strengthen governance
Both leaders are passionate supporters of the Ontario life science sector, have broad industry experience and decades of work with entrepreneurial ventures.
Prospects Oncology Fund seeds developing pipeline of Ontario-based biotech innovations
With an expanding portfolio of breakthrough innovations, FACIT is committed to supporting Ontario entrepreneurs through the latest round of its Prospects Oncology Fund.
World-leading genomics cloud computing group builds clinical tool for cancer care in Ontario
Derived from a leading oncology bio-computing group and leveraging insights from the world’s largest cancer genomics projects, Ziliomics develops web-based, modular software platforms that help physicians make actionable treatment decisions for patients living with cancer.
Entrepreneur adds US oncology management experience to Ontario commercialization.
Dr O’Neill brings two decades of cancer drug development and seed stage investment experience, as well as an extensive business network in pharma and biotech.
Dr. Laszlo Radvanyi's industry expertise & network aligns well with OICR and FACIT's shared vision.
FACIT looks forward to working with Dr. Radvanyi on translating Ontario’s breakthrough oncology innovations.
Restorative Breast Cancer Solution Start-Up Wins the 2018 FACIT Pitch Competition.
Biotechnology competition modeled after popular TV program Dragons' Den.
FACIT’s Prospects Oncology Fund invests $450k in promising Ontario breakthrough technologies.
Investment supports emerging entrepreneurial scientists and critical proof-of-principle studies.
Saying goodbye to FACIT's friend and visionary-in-chief.
Jeff was a fantastic leader in the OICR-FACIT family and the broader Ontario life sciences community.
Seeding world class oncology innovation: a look back at 2017
We hope 2017 was a prosperous year for you, our partners in health innovation. While FACIT had many successes this year.....
FACIT congratulates OICR on launching CTIP to drive Ontario's most promising cancer drugs towards the clinic.
The Clinical Therapeutics Innovation Pipeline (CTIP) will support the local translation of Ontario discoveries into therapies with the potential for improving the lives of patients with cancer. Ten projects were selected in this highly competitive funding round, and reflect the strength of the province’s collaborative network and drug discoveries.
FACIT expands Board to advance mandate to drive Ontario cancer breakthroughs.
New Trustees join existing Trustees, Mr. Greg Gubitz and Mr. John Morrison, bringing additional financial, entrepreneurial and biotech industry expertise.
FACIT Congratulates Portfolio Company Turnstone Biologics on Transformative Collaboration with AbbVie
Turnstone Biologics, a startup co-founded by FACIT, announced a research, option and license agreement with AbbVie Inc. for up to three of Turnstone's next-gen oncolytic viral immunotherapies. This partnership deepens the Ontario roots established by FACIT and its co-founders, expanding the scale of innovative research and local career opportunities for scientists.
Addition of new investors builds on Ontario’s next-gen radiotherapies and cancer innovations
FACIT congratulates Fusion on completing the second closing of their Series A, now oversubscribed at US$46M, with new investors joining including Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc. FACIT participated in both, this latest closing and as an early seed investor in Fusion.
FACIT Launches Cross-border Campaign to Recruit Clinical Scientists and Biotechnology Industry Executives
Initiative targets expats for growing oncology company portfolio in Ontario
FACIT is expanding and updating its database of US-based industry advisors for roles ranging from investment diligence to full time management roles in Ontario-based biotech start-ups.
FACIT invests first round of Prospects Fund in Radialis Medical, KA Imaging, and DNAstack.
Ontario start-ups Radialis Medical of Thunder Bay, KA Imaging of Kitchener, and DNAstack of Toronto are the first to receive capital from FACIT's new Prospects Oncology Fund for proof-of-concept development of breakthrough cancer technologies.
Anil Amlani expands FACIT’s oncology expertise in medical device sector
Anil Amlani joins FACIT with strong executive and transactional experience, broadening the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.
First Patient Treated in Turnstone's Lung Cancer Trial Combining Novel Viral Cancer Therapy with Approved Checkpoint Inhibitor
Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing.
Turnstone announced that treatment has been initiated on the first patient in the company's Phase I/II clinical trial combining its novel oncolytic viral immunotherapy agent, MG1-MAGEA3, with pembrolizumab, an approved anti-PD-1 antibody.
Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development.
Seed funding from FACIT enables Propellon to accelerate the nomination of a candidate drug and position the Company for financing and/or entering a strategic partnership for clinical trials in patients with haematological cancers.
New evergreen fund to help Ontario discoveries reach seed-stage funding faster.
FACIT announces the launch of The Prospects Oncology Fund, designed to advance early-stage Ontario cancer discoveries by supporting the proof-of-concept studies needed to attract seed-stage investment.
Financing leverages and strengthens Ontario’s next-generation radiotherapeutics expertise, products.
FACIT and OICR report that Fusion Pharmaceuticals Inc. has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. as the lead investor. Additionally, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT.
The new collaboration provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.
Triphase Accelerator Corporation announced a new strategic collaboration with Celgene Corporation, that provides Celgene with an option to acquire all Triphase Accelerator’s assets relating to TRPH 222 (CD22-4AP), an antibody-drug conjugate in development for lymphoma.
Marizomib is a novel brain-penetrant proteasome inhibitor in development for patients with glioblastoma and relapsed and/or refractory multiple myeloma
Triphase Accelerator Announces that Celgene Corporation has acquired the company's assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
OrbiMed, Versant-led round continues commercialization success for Turnstone’s cancer therapies
FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.
Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic
Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.
FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers
The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.
Integrating innovative data privacy expertise with a global healthcare information & technology service leader, strengthening and driving Ontario’s digital healthcare security footprint.
The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.
Two New Clinical Trials to Be Initiated for Recurrent and Newly Diagnosed Malignant Gliomas
Triphase is expanding its current collaboration with Celgene in the development of marizomib for the potential treatment of malignant gliomas.
Combined entity creates strong foundation for leading Canadian immuno-oncology company.
Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.
Image-guided medicines for hard to treat cancers built using next generation medical isotopes.
FACIT's investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.
First-in-class epigenetic modifiers discovered by OICR positioned for collaborative development.
FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.
Triphase Accelerator Corporation Announces FDA Orphan Drug Designation for Marizomib in Malignant Glioma
Orphan drug designation granted by the FDA recognizes the unique potential of marizomib to benefit patients with malignant glioma.
Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.
FACIT Startup Turnstone Biologics Closes $11M Financing, Secures Additional Capital Commitment, and Adds Strong Management
Completion of a Series A financing round enables appointment of Dr. Sammy Farah as CEO and Dr. Brian Lichty as CTO.
Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential.
OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers
Research Collaboration and Option and License Agreement Reach Approximately $450 Million Cdn.
OICR, UHN, Novera Therapeutics collaborate with Johnson & Johnson Innovation to accelerate the development drug candidates for haematological cancers.
Marabex™ trial to assess the safety of a novel tumour-targeted oncolytic virus vaccine in patients with advanced solid tumours
Turnstone Biologics Inc., a FACIT portfolio company, has announced the ongoing enrollment of the Marabex™ clinical trial assessing the safety and immune responses in patients with advanced or metastatic, MAGE-A3-expressing solid tumours.
Fluorinov Pharma and FACIT announce the appointment of Luke M. Beshar, to Fluorinov's Board of Directors.
Mr. Beshar's appointment strengthens Fluorinov’s leadership team, adding financial and pharmaceutical industry expertise as Fluorinov accelerates its clinical development activities.
Turnstone Biologics Inc. to Accelerate Clinical and Commercial Translation of Cancer Immunotherapies
FACIT partners with Ontario researchers to create new company.
FACIT and its partners are pleased to announce the formation of Turnstone Biologics Inc., a biotechnology company focussed on developing treatments for cancer that harness the patient’s own immune system.
Roger J Garceau Joins Fluorinov Board, Adds Clinical Expertise to Bromodomain Program and Oncology Pipeline
Fluorinov Pharma and FACIT announce the appointment of Dr. Roger J Garceau, to Fluorinov's Board of Directors.
With extensive experience guiding biotech companies in matters including corporate development and clinical strategy, Dr. Garceau's appointment strengthens Fluorinov’s leadership team and adds significant regulatory expertise as Fluorinov transitions to clinical development.
Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers
FACIT invests in Fluorinov Pharma's novel anti-cancer bromodomain inhibitors and disruptive potential of its technology platform.
TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets.
FACIT is planning its Falcons’ Fortunes pitch competition in 2015.
On Wednesday, March 11, 2015, FACIT invites you to pitch your idea to a panel of sharp-eyed yet friendly investors. Hosted by the commercially savvy FACIT Falcons, this event is offering $50,000 in Catalyst Funding to invest in the most promising oncology research idea.
FACIT-supported Xagenic Inc is a chip-based diagnostic screening company.
BDC Capital joined as a new investor and Dion Madsen, Senior Managing Partner at BDC Capital, will join Xagenic’s Board of Directors.
XLV Diagnostics Inc. specializes in low-cost, next-generation digital mammography machines.
XLV, a MaRS Innovation start-up company based in Thunder Bay, closed a $3 million Series A investment round with Boston-based Bernard M. Gordon Charitable Remainder Unitrust.
Fluorinov has developed three structurally distinct candidate drugs intended to treat cancer pain and brain cancer-related epilepsy.
The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects.
High-parameter single-cell protein analysis platform joins with industry-leading single-cell genomics platforms.
With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms.
A Unique Collaboration of Life Science Leaders has formed Triphase Accelerator Corporation to be an Oncology Development Accelerator.
Triphase was spun out of the Ontario Institute for Cancer Research to develop and advance late pre-clinical, Phase I or early Phase II potential products.
Funding of $1.5 million will be used to further develop a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.
Cellax™, invented by OICR researchers, is a drug-polymer conjugate based on the proprietary NanoCMC™ technology.
OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers.
OICR will provide $1.5 million for the development of FV-162, a highly potent, orally-delivered small molecule proteasome inhibitor for multiple myeloma and some forms of Non-Hodgkin’s lymphoma.
OICR-supported Xagenic Inc is a new chip-based diagnostic screening company.
Investors in the Series A round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario Capital Growth Corporation through its Emerging Technologies Fund.